{"gene":"NPAS3","run_date":"2026-06-10T05:19:52","timeline":{"discoveries":[{"year":2016,"finding":"Crystal structures of multi-domain NPAS3-ARNT-DNA complexes reveal that NPAS3 must heterodimerize with ARNT to form functional transcription complexes capable of DNA binding and gene regulation, and that the complex contains four putative ligand-binding pockets, implicating NPAS3 as a multi-ligand-binding transcription factor.","method":"X-ray crystallography of multi-domain NPAS3-ARNT-DNA complexes","journal":"eLife","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structure of multi-domain complex with DNA, architectural comparisons across multiple bHLH-PAS family members in a single rigorous structural study","pmids":["27782878"],"is_preprint":false},{"year":2018,"finding":"NPAS3 directly interacts with ARNT through both bHLH and PAS dimerization domains in human cells; the C-terminus of NPAS3 contains a functional transactivation domain; and the NPAS3::ARNT heterodimer directly binds the proximal promoters of VGF and TXNIP to regulate their expression.","method":"Co-immunoprecipitation, reporter gene assays, promoter binding assays, domain deletion/truncation analysis in human cells","journal":"BMC molecular biology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — reciprocal co-IP confirming ARNT interaction, combined with reporter assays and promoter binding, multiple orthogonal methods in one study","pmids":["30509165"],"is_preprint":false},{"year":2011,"finding":"NPAS3 overexpression in HEK293 cells upregulates VGF as its most highly induced transcriptional target, and represses multiple glycolysis genes; knockout mouse brain tissue shows altered levels of NAD+, glycolysis metabolites (dihydroxyacetone phosphate, fructose-1,6-bisphosphate), pentose phosphate pathway components, and Krebs cycle intermediates (succinate, α-ketoglutarate), confirming NPAS3's dual role in neurodevelopmental gene regulation and glucose metabolism.","method":"Microarray transcriptomics of NPAS3-overexpressing HEK293 cells; high-resolution mass spectrometry metabolomics of Npas3 KO vs. wild-type mouse brain tissue; immunofluorescence localization","journal":"Molecular psychiatry","confidence":"High","confidence_rationale":"Tier 2 / Strong — transcriptomic and metabolomic approaches independently validated, with KO confirmation; two orthogonal methods in same study","pmids":["21709683"],"is_preprint":false},{"year":2016,"finding":"NPAS3 regulates VGF expression through the NF-κB signaling pathway rather than solely by direct E-box binding; a κB site within the VGF promoter mediates NPAS3-induced VGF activation, and ectopic NPAS3 expression increases NF-κB (P65) levels. NPAS3-driven cell proliferation can be blocked by VGF knockdown.","method":"Reporter assays with mutated E-box and κB sites in VGF promoter; western blotting for NF-κB; VGF knockdown proliferation assays in PC12 cells","journal":"Frontiers in molecular neuroscience","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple reporter assays with site mutations and knockdown rescue, single lab","pmids":["27877109"],"is_preprint":false},{"year":2009,"finding":"NPAS3 is a functional homolog of Drosophila Trachealess and is required for lung branching morphogenesis; in Npas3-null mice, Shh, Fgf9, Fgf10, and Bmp4 mRNAs are decreased and Spry2 is increased. In promoter reporter assays, NPAS3 directly upregulates Shh transcription and represses Spry2 transcription. Exogenous FGF10 rescues branching morphogenesis in Npas3-null lungs.","method":"Npas3-null mouse characterization; promoter reporter assays; exogenous FGF10 rescue experiment; quantitative mRNA analysis","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — KO mouse with defined molecular phenotype, promoter reporter assays, and rescue experiment; multiple orthogonal methods","pmids":["19581591"],"is_preprint":false},{"year":2004,"finding":"NPAS3 is expressed in inhibitory interneurons in the brain, and NPAS3-deficient mice show a distinct reduction in reelin expression, indicating that NPAS3 (together with NPAS1) controls a regulatory program in inhibitory interneurons that governs reelin production.","method":"Immunohistochemical staining; NPAS1/NPAS3 double-knockout mouse characterization; behavioral testing (prepulse inhibition, locomotor activity, social recognition)","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — IHC localization combined with KO mouse showing specific molecular deficit in reelin; single lab","pmids":["15347806"],"is_preprint":false},{"year":2005,"finding":"Npas3-null mice display developmental brain abnormalities (reduced anterior hippocampus, corpus callosum hypoplasia, enlarged ventricles) and altered cortical PSD-95 expression, indicating that NPAS3 controls normal brain development and postsynaptic signaling pathways involving glutamate, dopamine, and serotonin neurotransmission.","method":"Npas3 knockout mouse generation and characterization; behavioral testing; pharmacological probing of neurotransmitter systems; western blotting for PSD-95","journal":"The European journal of neuroscience","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — KO mouse with defined neuroanatomical and molecular phenotype; single lab with multiple behavioral and molecular readouts","pmids":["16190882"],"is_preprint":false},{"year":2011,"finding":"NPAS3 immunoreactivity is localized to the hippocampal subgranular zone (site of adult neurogenesis) in maturing but not proliferating neuronal precursor cells, indicating a role for NPAS3 in the maturation phase of adult hippocampal neurogenesis.","method":"Immunofluorescence localization in mouse brain; combined with microarray and metabolomics in the same study","journal":"Molecular psychiatry","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — direct immunofluorescence localization with cell-type resolution, replicated in same study with multiple orthogonal methods","pmids":["21709683"],"is_preprint":false},{"year":2016,"finding":"The V304I mutation in NPAS3, segregating with schizophrenia in a small family, increases NPAS3 protein aggregation propensity in both bacterial and mammalian expression systems, reduces soluble endogenous NPAS3, increases insoluble endogenous NPAS3, and alters its transcriptional activity.","method":"Expression of wild-type vs. V304I NPAS3 in bacterial and mammalian systems; soluble/insoluble fractionation; western blotting; transcriptional reporter assays","journal":"Molecular neuropsychiatry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple expression systems and orthogonal readouts (aggregation, fractionation, transcriptional activity); single lab","pmids":["27867938"],"is_preprint":false},{"year":2021,"finding":"Loss-of-function truncation variants of NPAS3 abolish transcriptional activity when partnered with ARNT2, and the mechanism is the inability of truncated NPAS3 to heterodimerize with ARNT2, as confirmed by co-immunoprecipitation.","method":"Reporter gene transcriptional activity assays; co-immunoprecipitation with ARNT2; clinical exome sequencing database variants","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional reporter assays combined with co-IP mechanistic dissection; single lab, two orthogonal methods","pmids":["33758288"],"is_preprint":false},{"year":2021,"finding":"NPAS3 aggregation into an insoluble form is a widespread phenomenon in human insular cortex (detected in 70% of samples), is not limited to the V304I mutation, and oxidative stress plays a larger mechanistic role than the V304I mutation in promoting aggregation in neuroblastoma cells.","method":"Insoluble fraction purification from postmortem human cortex; western blotting; oxidative stress induction in neuroblastoma cells; fractionation","journal":"Journal of personalized medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct biochemical fractionation of postmortem human brain tissue plus cellular mechanistic experiments; single lab","pmids":["34834422"],"is_preprint":false},{"year":2012,"finding":"miR-17 post-transcriptionally regulates NPAS3 by binding to the NPAS3 3' UTR, as demonstrated by luciferase reporter assays, contributing to the dissociation between declining NPAS3 mRNA and increasing NPAS3 protein during human postnatal cortical development.","method":"Luciferase reporter assays with NPAS3 3' UTR; western blotting; microarray and qRT-PCR in postmortem human brain tissue","journal":"Schizophrenia bulletin","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct reporter assay demonstrating functional miR-17 binding to 3' UTR, validated in human postmortem tissue; single lab","pmids":["22228753"],"is_preprint":false},{"year":2022,"finding":"NPAS3 is a critical regulator of astrogenesis in the developing cortex; Npas3 knockout impairs the differentiation trajectory from radial glia to astrocytes (shown by single-cell transcriptomics). ChIP-seq in primary cortical astrocytes shows NPAS3 binds chromatin targets involved in brain development and synapse organization. Astrocyte-specific Npas3 knockdown causes synaptic and behavioral deficits, and NPAS3-impaired astrogenesis induces synaptic deficits in wild-type neurons in co-culture.","method":"Npas3 KO mouse; single-cell RNA-seq; ChIP-seq in primary cortical astrocytes; astrocyte-specific in vivo knockdown; neuron-astrocyte co-culture assay; behavioral testing","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (scRNA-seq, ChIP-seq, in vivo KD, co-culture), cell-type-specific dissection of mechanism","pmids":["36044858"],"is_preprint":false},{"year":2022,"finding":"Npas3 knockdown in cortical neural progenitor cells impairs neuronal radial migration, changes laminar cell fate, and promotes stemness maintenance and increased proliferation of radial glial cells in the VZ/SVZ, indicating that Npas3 regulates the transition from progenitor proliferation to neuronal differentiation and migration in the developing cerebral cortex.","method":"In utero knockdown of Npas3 in cortical VZ progenitors; histological and immunofluorescence analysis of cortical lamination and progenitor markers","journal":"Frontiers in cellular neuroscience","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo loss-of-function with defined cellular phenotypes; single lab, single primary method","pmids":["36313621"],"is_preprint":false},{"year":2023,"finding":"A covalent compound (Compound 6) blocks NPAS3-ARNT heterodimer formation by covalently binding to ARNT Cys336, effectively down-regulating NPAS3 transcriptional function at the cellular level; this identifies ARNT Cys336 as the binding site and the 5-nitrothiazole-2-sulfydryl group as a cysteine-targeting warhead for disrupting the NPAS3-ARNT interface.","method":"Biochemical NPAS3-ARNT heterodimer formation assay (EC50 measurement); cellular transcriptional reporter assays; covalent inhibitor medicinal chemistry and structure-activity relationship","journal":"Bioorganic chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — biochemical and cellular assays identifying specific covalent binding site on ARNT; single lab, two orthogonal assay levels","pmids":["37352720"],"is_preprint":false},{"year":2026,"finding":"In astrocytes, AEBP1 sequesters NPAS3 in the cytoplasm, preventing its nuclear binding to the Lipa promoter; when AEBP1 is overexpressed, NPAS3 fails to activate LIPA transcription, leading to lipid droplet accumulation, excess cholesteryl ester storage, lysosomal Aβ retention, and worsened Alzheimer's pathology in 5×FAD mice.","method":"Astrocyte-specific AEBP1 knockdown/overexpression in 5×FAD mice; hippocampal transcriptomics and metabolomics; LIPA promoter binding assay; NPAS3 cytoplasmic sequestration demonstrated by protein localization; in vitro cultured astrocyte experiments","journal":"Cell reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo and in vitro mechanistic dissection with promoter binding evidence; single lab, multiple orthogonal approaches","pmids":["41880326"],"is_preprint":false},{"year":2020,"finding":"NPAS3 functions as a direct target of miR-122 in endothelial cells; NPAS3 silencing abolishes the anti-EndMT (endothelial-to-mesenchymal transition) effect of miR-122 inhibition, placing NPAS3 downstream of miR-122 in the regulation of EndMT and atherosclerosis.","method":"miR-122 mimic/inhibitor transfection in endothelial cells; NPAS3 siRNA knockdown; western blotting for endothelial and mesenchymal markers; lenti-virus injection in ApoE-/- mice","journal":"Life sciences","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — epistasis established by NPAS3 knockdown rescuing miR-122 inhibitor phenotype; in vitro and in vivo; single lab","pmids":["33278397"],"is_preprint":false},{"year":2025,"finding":"The lncRNA 3222401L13Rik mediates its effects on astrocyte neuronal-support gene expression through interaction with NPAS3; overexpression of NPAS3 rescues the functional deficits in astrocytes caused by 3222401L13Rik knockdown.","method":"lncRNA knockdown in primary astrocytes; NPAS3 overexpression rescue assay; interaction between lncRNA and NPAS3 demonstrated","journal":"Non-coding RNA","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single lab, rescue experiment supporting interaction but mechanism of lncRNA-NPAS3 interaction not fully characterized at molecular level from abstract","pmids":["39846680"],"is_preprint":false}],"current_model":"NPAS3 is a bHLH-PAS transcription factor that obligatorily heterodimerizes with ARNT (via bHLH and PAS domains) to bind DNA and activate target genes including VGF, SHH, and LIPA while repressing SPRY2 and glycolysis genes; its crystal structure reveals four putative ligand-binding pockets; it is regulated post-transcriptionally by miR-17 and post-translationally by cytoplasmic sequestration via AEBP1; it controls adult hippocampal neurogenesis (acting in maturing rather than proliferating precursors), cortical astrogenesis, lung branching morphogenesis via FGF/SHH signaling, and endothelial-mesenchymal transition; and disease-associated mutations or oxidative stress promote its aggregation into insoluble forms that reduce functional soluble NPAS3 and alter transcriptional activity."},"narrative":{"mechanistic_narrative":"NPAS3 is a bHLH-PAS transcription factor that governs neurodevelopmental and metabolic gene programs by obligatorily heterodimerizing with ARNT to bind DNA and regulate target genes [PMID:27782878, PMID:30509165]. Crystal structures of multi-domain NPAS3-ARNT-DNA complexes establish that productive DNA binding requires the heterodimer and reveal four putative ligand-binding pockets, defining NPAS3 as a candidate multi-ligand-sensing factor [PMID:27782878]; dimerization occurs through both the bHLH and PAS domains, while a C-terminal transactivation domain drives gene activation [PMID:30509165]. Through this complex NPAS3 activates targets including VGF and Shh and represses Spry2 and multiple glycolysis genes, coupling neurodevelopmental transcription to glucose metabolism [PMID:30509165, PMID:21709683, PMID:19581591]. NPAS3 is required for lung branching morphogenesis via FGF/SHH signaling, with exogenous FGF10 rescuing the Npas3-null defect [PMID:19581591], and it controls cortical development by regulating progenitor-to-neuron transitions, radial migration, and astrogenesis, where ChIP-seq defines targets in brain development and synapse organization [PMID:36044858, PMID:36313621]. Its activity is constrained post-transcriptionally by miR-17 binding to the 3' UTR [PMID:22228753] and post-translationally by AEBP1-mediated cytoplasmic sequestration, which blocks NPAS3 from activating Lipa and promotes lipid and amyloid pathology in astrocytes [PMID:41880326]. Disease-associated truncation variants abolish transcriptional activity by preventing ARNT2 heterodimerization [PMID:33758288], and the schizophrenia-segregating V304I mutation, like oxidative stress, drives NPAS3 into insoluble aggregates that deplete functional soluble protein [PMID:27867938, PMID:34834422].","teleology":[{"year":2004,"claim":"Established that NPAS3 operates within inhibitory interneurons to govern a specific molecular program, moving it from an orphan factor to a defined neuronal regulator.","evidence":"Immunohistochemistry plus NPAS1/NPAS3 double-knockout mice showing reduced reelin expression and behavioral deficits","pmids":["15347806"],"confidence":"Medium","gaps":["Does not show direct binding of NPAS3 to the reelin gene","Confounded by simultaneous loss of NPAS1"]},{"year":2005,"claim":"Defined the in vivo developmental consequence of NPAS3 loss, linking it to brain morphogenesis and postsynaptic signaling.","evidence":"Npas3 knockout mouse with neuroanatomical defects, altered PSD-95, and neurotransmitter pharmacology","pmids":["16190882"],"confidence":"Medium","gaps":["Phenotypes are downstream and do not identify direct transcriptional targets","Mechanism connecting NPAS3 to PSD-95 unresolved"]},{"year":2009,"claim":"Identified direct transcriptional targets of NPAS3 and a tissue role outside the brain, showing it activates Shh and represses Spry2 to drive FGF/SHH-dependent lung branching.","evidence":"Npas3-null mouse with reduced Shh/Fgf9/Fgf10/Bmp4 and increased Spry2, promoter reporter assays, and FGF10 rescue","pmids":["19581591"],"confidence":"High","gaps":["Did not resolve the dimerization partner required for these promoter activities","Direct E-box occupancy in vivo not mapped"]},{"year":2011,"claim":"Connected NPAS3 transcription to metabolism and localized it to the maturation phase of adult neurogenesis, revealing a dual neurodevelopmental and metabolic role.","evidence":"Microarray of NPAS3-overexpressing HEK293 cells (VGF induction, glycolysis repression), KO mouse brain metabolomics, and subgranular-zone immunofluorescence","pmids":["21709683"],"confidence":"High","gaps":["Metabolic gene repression not shown to be via direct promoter binding","Mechanism linking NPAS3 to NAD+/Krebs intermediates unresolved"]},{"year":2012,"claim":"Explained the post-transcriptional uncoupling of NPAS3 mRNA and protein during cortical development by identifying miR-17 control of its 3' UTR.","evidence":"Luciferase 3' UTR reporter assays plus expression profiling in postmortem human cortex","pmids":["22228753"],"confidence":"Medium","gaps":["Does not establish whether miR-17 regulation alters NPAS3 transcriptional output","Single miRNA examined"]},{"year":2016,"claim":"Solved the structural and mechanistic basis of NPAS3 DNA binding, proving obligate ARNT heterodimerization and revealing candidate ligand pockets.","evidence":"X-ray crystallography of multi-domain NPAS3-ARNT-DNA complexes","pmids":["27782878"],"confidence":"High","gaps":["Endogenous ligands for the four pockets unidentified","Does not address tissue-specific cofactor selection"]},{"year":2016,"claim":"Refined the VGF activation mechanism, showing NPAS3 acts in part through NF-κB signaling rather than solely direct E-box binding, and links VGF to proliferation.","evidence":"Reporter assays with mutated E-box/κB sites, NF-κB western blotting, and VGF-knockdown proliferation assays in PC12 cells","pmids":["27877109"],"confidence":"Medium","gaps":["Direct vs. indirect NF-κB induction not distinguished","Single cell-line system"]},{"year":2016,"claim":"Introduced protein aggregation as a disease mechanism, showing a schizophrenia-segregating mutation increases NPAS3 insolubility and alters its activity.","evidence":"Wild-type vs. V304I expression in bacterial and mammalian systems, solubility fractionation, and reporter assays","pmids":["27867938"],"confidence":"Medium","gaps":["Causality from a single small family","Structural basis of aggregation not defined"]},{"year":2018,"claim":"Mapped the NPAS3-ARNT interaction to both bHLH and PAS domains and localized the transactivation function and direct VGF/TXNIP promoter binding.","evidence":"Reciprocal Co-IP, domain truncation, reporter and promoter binding assays in human cells","pmids":["30509165"],"confidence":"High","gaps":["Does not establish in vivo occupancy at these promoters","Regulation of TXNIP physiologic context unexplored"]},{"year":2021,"claim":"Established loss-of-function disease variants act by abolishing heterodimerization, tying clinical truncations directly to the dimerization requirement.","evidence":"Reporter transcriptional assays and Co-IP with ARNT2 for clinical truncation variants","pmids":["33758288"],"confidence":"Medium","gaps":["Patient phenotype-to-molecular-defect correlation limited","ARNT vs. ARNT2 partner preference in vivo unresolved"]},{"year":2021,"claim":"Generalized NPAS3 aggregation beyond a single mutation, implicating oxidative stress as the dominant driver in human cortex.","evidence":"Insoluble-fraction purification from postmortem human insular cortex and oxidative-stress induction in neuroblastoma cells","pmids":["34834422"],"confidence":"Medium","gaps":["Functional consequence of widespread aggregation on neuronal physiology unmeasured","Trigger of oxidative-stress-driven aggregation in vivo unknown"]},{"year":2022,"claim":"Defined a cell-autonomous role in astrogenesis with genome-wide target mapping, showing NPAS3 in astrocytes is needed for synapse organization and behavior.","evidence":"Npas3 KO single-cell RNA-seq, astrocyte ChIP-seq, astrocyte-specific in vivo knockdown, and neuron-astrocyte co-culture","pmids":["36044858"],"confidence":"High","gaps":["Individual functional targets among ChIP-seq peaks not validated","Dependence on ARNT partner in astrocytes not tested"]},{"year":2022,"claim":"Showed NPAS3 controls the progenitor-to-neuron transition, regulating proliferation, fate, and radial migration in developing cortex.","evidence":"In utero knockdown in cortical VZ progenitors with lamination and progenitor-marker analysis","pmids":["36313621"],"confidence":"Medium","gaps":["Direct transcriptional targets in progenitors not identified","Single primary method"]},{"year":2020,"claim":"Placed NPAS3 downstream of miR-122 in vascular biology, extending its role to endothelial-to-mesenchymal transition and atherosclerosis.","evidence":"miR-122 mimic/inhibitor with NPAS3 siRNA epistasis in endothelial cells and ApoE-/- mouse experiments","pmids":["33278397"],"confidence":"Medium","gaps":["Direct miR-122 binding to NPAS3 transcript versus indirect effect not fully resolved","Transcriptional targets mediating EndMT unidentified"]},{"year":2023,"claim":"Provided pharmacological proof that disrupting the NPAS3-ARNT interface is feasible, identifying ARNT Cys336 as a covalent targeting site.","evidence":"Biochemical heterodimer-formation assay and cellular reporter assays with a covalent 5-nitrothiazole-2-sulfydryl compound","pmids":["37352720"],"confidence":"Medium","gaps":["Selectivity over other ARNT-dependent dimers untested","In vivo efficacy not demonstrated"]},{"year":2026,"claim":"Revealed post-translational control of NPAS3 by cytoplasmic sequestration, linking AEBP1-blocked LIPA activation to astrocyte lipid handling and Alzheimer's pathology.","evidence":"Astrocyte-specific AEBP1 knockdown/overexpression in 5xFAD mice, transcriptomics/metabolomics, LIPA promoter binding, and localization assays","pmids":["41880326"],"confidence":"Medium","gaps":["Direct physical AEBP1-NPAS3 interaction interface not mapped","Single disease model"]},{"year":null,"claim":"The endogenous ligands occupying the four NPAS3-ARNT pockets and how ligand or partner choice (ARNT vs ARNT2) selects target programs across neurons, astrocytes, lung, and endothelium remain unknown.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No identified physiological ligand for the structural pockets","Determinants of cell-type-specific target selection unresolved","Relationship between aggregation, sequestration, and transcriptional output not unified mechanistically"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[0,1,2,4,12]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[0,1,12]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[0,1,15]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[15]}],"pathway":[{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[0,1,4,12]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[4,12,13]}],"complexes":["NPAS3-ARNT heterodimer"],"partners":["ARNT","ARNT2","AEBP1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q8IXF0","full_name":"Neuronal PAS domain-containing protein 3","aliases":["Basic-helix-loop-helix-PAS protein MOP6","Class E basic helix-loop-helix protein 12","bHLHe12","Member of PAS protein 6","PAS domain-containing protein 6"],"length_aa":933,"mass_kda":100.8,"function":"May play a broad role in neurogenesis. May control regulatory pathways relevant to schizophrenia and to psychotic illness (By similarity)","subcellular_location":"Nucleus","url":"https://www.uniprot.org/uniprotkb/Q8IXF0/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/NPAS3","classification":"Not Classified","n_dependent_lines":7,"n_total_lines":1208,"dependency_fraction":0.005794701986754967},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/NPAS3","total_profiled":1310},"omim":[{"mim_id":"609947","title":"PROTEIN ONLY RNASE P CATALYTIC SUBUNIT; PRORP","url":"https://www.omim.org/entry/609947"},{"mim_id":"609430","title":"NEURONAL PAS DOMAIN PROTEIN 3; NPAS3","url":"https://www.omim.org/entry/609430"},{"mim_id":"181500","title":"SCHIZOPHRENIA; SCZD","url":"https://www.omim.org/entry/181500"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in some","driving_tissues":[{"tissue":"brain","ntpm":12.8},{"tissue":"cervix","ntpm":5.7}],"url":"https://www.proteinatlas.org/search/NPAS3"},"hgnc":{"alias_symbol":["MOP6","PASD6","bHLHe12"],"prev_symbol":[]},"alphafold":{"accession":"Q8IXF0","domains":[{"cath_id":"3.30.450.20","chopping":"95-114_139-213_258-317","consensus_level":"medium","plddt":86.7791,"start":95,"end":317},{"cath_id":"3.30.450.20","chopping":"328-447","consensus_level":"medium","plddt":92.9788,"start":328,"end":447}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q8IXF0","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q8IXF0-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q8IXF0-F1-predicted_aligned_error_v6.png","plddt_mean":55.25},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=NPAS3","jax_strain_url":"https://www.jax.org/strain/search?query=NPAS3"},"sequence":{"accession":"Q8IXF0","fasta_url":"https://rest.uniprot.org/uniprotkb/Q8IXF0.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q8IXF0/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q8IXF0"}},"corpus_meta":[{"pmid":"15347806","id":"PMC_15347806","title":"Behavioral and regulatory abnormalities in mice deficient in the NPAS1 and NPAS3 transcription factors.","date":"2004","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/15347806","citation_count":144,"is_preprint":false},{"pmid":"18521090","id":"PMC_18521090","title":"Association of the NPAS3 gene and five other loci with response to the antipsychotic iloperidone identified in a whole genome association study.","date":"2008","source":"Molecular psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/18521090","citation_count":114,"is_preprint":false},{"pmid":"18317462","id":"PMC_18317462","title":"Interacting haplotypes at the NPAS3 locus alter risk of schizophrenia and bipolar disorder.","date":"2008","source":"Molecular psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/18317462","citation_count":84,"is_preprint":false},{"pmid":"23408798","id":"PMC_23408798","title":"The developmental brain gene NPAS3 contains the largest number of accelerated regulatory sequences in the human genome.","date":"2013","source":"Molecular biology and evolution","url":"https://pubmed.ncbi.nlm.nih.gov/23408798","citation_count":81,"is_preprint":false},{"pmid":"27782878","id":"PMC_27782878","title":"NPAS1-ARNT and NPAS3-ARNT crystal structures implicate the bHLH-PAS family as multi-ligand binding transcription factors.","date":"2016","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/27782878","citation_count":69,"is_preprint":false},{"pmid":"15924306","id":"PMC_15924306","title":"Disruption of a brain transcription factor, NPAS3, is associated with schizophrenia and learning disability.","date":"2005","source":"American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/15924306","citation_count":68,"is_preprint":false},{"pmid":"16190882","id":"PMC_16190882","title":"Abnormal neurodevelopment, neurosignaling and behaviour in Npas3-deficient mice.","date":"2005","source":"The European journal of neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/16190882","citation_count":63,"is_preprint":false},{"pmid":"10534623","id":"PMC_10534623","title":"Characterization of npas3, a novel basic helix-loop-helix PAS gene expressed in the developing mouse nervous system.","date":"1999","source":"Mechanisms of development","url":"https://pubmed.ncbi.nlm.nih.gov/10534623","citation_count":55,"is_preprint":false},{"pmid":"17008307","id":"PMC_17008307","title":"The NPAS3 gene--emerging evidence for a role in psychiatric illness.","date":"2006","source":"Annals of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/17008307","citation_count":44,"is_preprint":false},{"pmid":"20466522","id":"PMC_20466522","title":"Association of NPAS3 exonic variation with schizophrenia.","date":"2010","source":"Schizophrenia research","url":"https://pubmed.ncbi.nlm.nih.gov/20466522","citation_count":40,"is_preprint":false},{"pmid":"21709683","id":"PMC_21709683","title":"Transcriptional regulation of neurodevelopmental and metabolic pathways by NPAS3.","date":"2011","source":"Molecular psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/21709683","citation_count":36,"is_preprint":false},{"pmid":"24218632","id":"PMC_24218632","title":"A fast-evolving human NPAS3 enhancer gained reporter expression in the developing forebrain of transgenic mice.","date":"2013","source":"Philosophical transactions of the Royal Society of London. Series B, Biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/24218632","citation_count":35,"is_preprint":false},{"pmid":"33278397","id":"PMC_33278397","title":"Inhibition of miR-122 reduced atherosclerotic lesion formation by regulating NPAS3-mediated endothelial to mesenchymal transition.","date":"2020","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33278397","citation_count":32,"is_preprint":false},{"pmid":"22228753","id":"PMC_22228753","title":"Expression of NPAS3 in the human cortex and evidence of its posttranscriptional regulation by miR-17 during development, with implications for schizophrenia.","date":"2012","source":"Schizophrenia bulletin","url":"https://pubmed.ncbi.nlm.nih.gov/22228753","citation_count":31,"is_preprint":false},{"pmid":"19581591","id":"PMC_19581591","title":"NPAS3 is a trachealess homolog critical for lung development and homeostasis.","date":"2009","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/19581591","citation_count":27,"is_preprint":false},{"pmid":"21703424","id":"PMC_21703424","title":"NPAS3 demonstrates features of a tumor suppressive role in driving the progression of Astrocytomas.","date":"2011","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/21703424","citation_count":26,"is_preprint":false},{"pmid":"27867938","id":"PMC_27867938","title":"A Mutation in NPAS3 That Segregates with Schizophrenia in a Small Family Leads to Protein Aggregation.","date":"2016","source":"Molecular neuropsychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/27867938","citation_count":22,"is_preprint":false},{"pmid":"36044858","id":"PMC_36044858","title":"Npas3 deficiency impairs cortical astrogenesis and induces autistic-like behaviors.","date":"2022","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/36044858","citation_count":20,"is_preprint":false},{"pmid":"21306425","id":"PMC_21306425","title":"Immunohistochemical analyses of NPAS3 expression in the developing human fetal brain.","date":"2011","source":"Anatomia, histologia, embryologia","url":"https://pubmed.ncbi.nlm.nih.gov/21306425","citation_count":16,"is_preprint":false},{"pmid":"27877109","id":"PMC_27877109","title":"NPAS3 Regulates Transcription and Expression of VGF: Implications for Neurogenesis and Psychiatric Disorders.","date":"2016","source":"Frontiers in molecular neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/27877109","citation_count":14,"is_preprint":false},{"pmid":"30509165","id":"PMC_30509165","title":"Molecular analysis of NPAS3 functional domains and variants.","date":"2018","source":"BMC molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/30509165","citation_count":12,"is_preprint":false},{"pmid":"33758288","id":"PMC_33758288","title":"Molecular characterisation of rare loss-of-function NPAS3 and NPAS4 variants identified in individuals with neurodevelopmental disorders.","date":"2021","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/33758288","citation_count":10,"is_preprint":false},{"pmid":"34834422","id":"PMC_34834422","title":"Protein Aggregation of NPAS3, Implicated in Mental Illness, Is Not Limited to the V304I Mutation.","date":"2021","source":"Journal of personalized medicine","url":"https://pubmed.ncbi.nlm.nih.gov/34834422","citation_count":9,"is_preprint":false},{"pmid":"36313621","id":"PMC_36313621","title":"Npas3 regulates stemness maintenance of radial glial cells and neuronal migration in the developing mouse cerebral cortex.","date":"2022","source":"Frontiers in cellular neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/36313621","citation_count":8,"is_preprint":false},{"pmid":"39846680","id":"PMC_39846680","title":"LncRNA 3222401L13Rik Is Upregulated in Aging Astrocytes and Regulates Neuronal Support Function Through Interaction with Npas3.","date":"2025","source":"Non-coding RNA","url":"https://pubmed.ncbi.nlm.nih.gov/39846680","citation_count":6,"is_preprint":false},{"pmid":"25862168","id":"PMC_25862168","title":"Lower NPAS3 expression during the later stages of abnormal lung development in rat congenital diaphragmatic hernia.","date":"2015","source":"Pediatric surgery international","url":"https://pubmed.ncbi.nlm.nih.gov/25862168","citation_count":5,"is_preprint":false},{"pmid":"23962688","id":"PMC_23962688","title":"Novel alternative splice variants of chicken NPAS3 are expressed in the developing central nervous system.","date":"2013","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/23962688","citation_count":5,"is_preprint":false},{"pmid":"25982957","id":"PMC_25982957","title":"Cumulative role of rare and common putative functional genetic variants at NPAS3 in schizophrenia susceptibility.","date":"2015","source":"American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/25982957","citation_count":5,"is_preprint":false},{"pmid":"37352720","id":"PMC_37352720","title":"Discovery of a highly potent NPAS3 heterodimer inhibitor by covalently modifying ARNT.","date":"2023","source":"Bioorganic chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/37352720","citation_count":2,"is_preprint":false},{"pmid":"24674381","id":"PMC_24674381","title":"NPAS3 variants in schizophrenia: a neuroimaging study.","date":"2014","source":"BMC medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/24674381","citation_count":2,"is_preprint":false},{"pmid":"37480305","id":"PMC_37480305","title":"SYMPTOM SEVERITY IN SCHIZOPHRENIA PATIENTS WITH NPAS3, DYSBINDIN-1 AND/OR TRIOBP PROTEIN PATHOLOGY IN THEIR BLOOD SERUM: A PANSS-BASED FOLLOW UP STUDY.","date":"2023","source":"Psychiatria Danubina","url":"https://pubmed.ncbi.nlm.nih.gov/37480305","citation_count":2,"is_preprint":false},{"pmid":"39241178","id":"PMC_39241178","title":"The Human Accelerated Region HAR202 Controls NPAS3 Expression in the Developing Forebrain Displaying Differential Enhancer Activity Between Modern and Archaic Human Sequences.","date":"2024","source":"Molecular biology and evolution","url":"https://pubmed.ncbi.nlm.nih.gov/39241178","citation_count":2,"is_preprint":false},{"pmid":"22110344","id":"PMC_22110344","title":"Isolation and Characterization of Chicken NPAS3.","date":"2010","source":"Experimental neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/22110344","citation_count":1,"is_preprint":false},{"pmid":"41880326","id":"PMC_41880326","title":"Astrocytic AEBP1-NPAS3-LIPA pathway coordinates cholesterol homeostasis to regulate Alzheimer's pathology.","date":"2026","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/41880326","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2024.08.14.607966","title":"LncRNA 3222401L13Rik Is Up-regulated in Aging Astrocytes and Regulates Neuronal Support Function Through Interaction with Npas3","date":"2024-08-19","source":"bioRxiv","url":"https://doi.org/10.1101/2024.08.14.607966","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.11.13.623439","title":"Regulatory plasticity of the human genome","date":"2024-11-14","source":"bioRxiv","url":"https://doi.org/10.1101/2024.11.13.623439","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":18581,"output_tokens":4647,"usd":0.062724,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":12760,"output_tokens":4600,"usd":0.0894,"stage2_stop_reason":"end_turn"},"total_usd":0.152124,"stage1_batch_id":"msgbatch_013a8chtv3AWyTqv4z4sEF4C","stage2_batch_id":"msgbatch_01AHsuW63vinsvuTgzmQ3n62","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2016,\n      \"finding\": \"Crystal structures of multi-domain NPAS3-ARNT-DNA complexes reveal that NPAS3 must heterodimerize with ARNT to form functional transcription complexes capable of DNA binding and gene regulation, and that the complex contains four putative ligand-binding pockets, implicating NPAS3 as a multi-ligand-binding transcription factor.\",\n      \"method\": \"X-ray crystallography of multi-domain NPAS3-ARNT-DNA complexes\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structure of multi-domain complex with DNA, architectural comparisons across multiple bHLH-PAS family members in a single rigorous structural study\",\n      \"pmids\": [\"27782878\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"NPAS3 directly interacts with ARNT through both bHLH and PAS dimerization domains in human cells; the C-terminus of NPAS3 contains a functional transactivation domain; and the NPAS3::ARNT heterodimer directly binds the proximal promoters of VGF and TXNIP to regulate their expression.\",\n      \"method\": \"Co-immunoprecipitation, reporter gene assays, promoter binding assays, domain deletion/truncation analysis in human cells\",\n      \"journal\": \"BMC molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal co-IP confirming ARNT interaction, combined with reporter assays and promoter binding, multiple orthogonal methods in one study\",\n      \"pmids\": [\"30509165\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"NPAS3 overexpression in HEK293 cells upregulates VGF as its most highly induced transcriptional target, and represses multiple glycolysis genes; knockout mouse brain tissue shows altered levels of NAD+, glycolysis metabolites (dihydroxyacetone phosphate, fructose-1,6-bisphosphate), pentose phosphate pathway components, and Krebs cycle intermediates (succinate, α-ketoglutarate), confirming NPAS3's dual role in neurodevelopmental gene regulation and glucose metabolism.\",\n      \"method\": \"Microarray transcriptomics of NPAS3-overexpressing HEK293 cells; high-resolution mass spectrometry metabolomics of Npas3 KO vs. wild-type mouse brain tissue; immunofluorescence localization\",\n      \"journal\": \"Molecular psychiatry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — transcriptomic and metabolomic approaches independently validated, with KO confirmation; two orthogonal methods in same study\",\n      \"pmids\": [\"21709683\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"NPAS3 regulates VGF expression through the NF-κB signaling pathway rather than solely by direct E-box binding; a κB site within the VGF promoter mediates NPAS3-induced VGF activation, and ectopic NPAS3 expression increases NF-κB (P65) levels. NPAS3-driven cell proliferation can be blocked by VGF knockdown.\",\n      \"method\": \"Reporter assays with mutated E-box and κB sites in VGF promoter; western blotting for NF-κB; VGF knockdown proliferation assays in PC12 cells\",\n      \"journal\": \"Frontiers in molecular neuroscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple reporter assays with site mutations and knockdown rescue, single lab\",\n      \"pmids\": [\"27877109\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"NPAS3 is a functional homolog of Drosophila Trachealess and is required for lung branching morphogenesis; in Npas3-null mice, Shh, Fgf9, Fgf10, and Bmp4 mRNAs are decreased and Spry2 is increased. In promoter reporter assays, NPAS3 directly upregulates Shh transcription and represses Spry2 transcription. Exogenous FGF10 rescues branching morphogenesis in Npas3-null lungs.\",\n      \"method\": \"Npas3-null mouse characterization; promoter reporter assays; exogenous FGF10 rescue experiment; quantitative mRNA analysis\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — KO mouse with defined molecular phenotype, promoter reporter assays, and rescue experiment; multiple orthogonal methods\",\n      \"pmids\": [\"19581591\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"NPAS3 is expressed in inhibitory interneurons in the brain, and NPAS3-deficient mice show a distinct reduction in reelin expression, indicating that NPAS3 (together with NPAS1) controls a regulatory program in inhibitory interneurons that governs reelin production.\",\n      \"method\": \"Immunohistochemical staining; NPAS1/NPAS3 double-knockout mouse characterization; behavioral testing (prepulse inhibition, locomotor activity, social recognition)\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — IHC localization combined with KO mouse showing specific molecular deficit in reelin; single lab\",\n      \"pmids\": [\"15347806\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Npas3-null mice display developmental brain abnormalities (reduced anterior hippocampus, corpus callosum hypoplasia, enlarged ventricles) and altered cortical PSD-95 expression, indicating that NPAS3 controls normal brain development and postsynaptic signaling pathways involving glutamate, dopamine, and serotonin neurotransmission.\",\n      \"method\": \"Npas3 knockout mouse generation and characterization; behavioral testing; pharmacological probing of neurotransmitter systems; western blotting for PSD-95\",\n      \"journal\": \"The European journal of neuroscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — KO mouse with defined neuroanatomical and molecular phenotype; single lab with multiple behavioral and molecular readouts\",\n      \"pmids\": [\"16190882\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"NPAS3 immunoreactivity is localized to the hippocampal subgranular zone (site of adult neurogenesis) in maturing but not proliferating neuronal precursor cells, indicating a role for NPAS3 in the maturation phase of adult hippocampal neurogenesis.\",\n      \"method\": \"Immunofluorescence localization in mouse brain; combined with microarray and metabolomics in the same study\",\n      \"journal\": \"Molecular psychiatry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — direct immunofluorescence localization with cell-type resolution, replicated in same study with multiple orthogonal methods\",\n      \"pmids\": [\"21709683\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"The V304I mutation in NPAS3, segregating with schizophrenia in a small family, increases NPAS3 protein aggregation propensity in both bacterial and mammalian expression systems, reduces soluble endogenous NPAS3, increases insoluble endogenous NPAS3, and alters its transcriptional activity.\",\n      \"method\": \"Expression of wild-type vs. V304I NPAS3 in bacterial and mammalian systems; soluble/insoluble fractionation; western blotting; transcriptional reporter assays\",\n      \"journal\": \"Molecular neuropsychiatry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple expression systems and orthogonal readouts (aggregation, fractionation, transcriptional activity); single lab\",\n      \"pmids\": [\"27867938\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Loss-of-function truncation variants of NPAS3 abolish transcriptional activity when partnered with ARNT2, and the mechanism is the inability of truncated NPAS3 to heterodimerize with ARNT2, as confirmed by co-immunoprecipitation.\",\n      \"method\": \"Reporter gene transcriptional activity assays; co-immunoprecipitation with ARNT2; clinical exome sequencing database variants\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional reporter assays combined with co-IP mechanistic dissection; single lab, two orthogonal methods\",\n      \"pmids\": [\"33758288\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"NPAS3 aggregation into an insoluble form is a widespread phenomenon in human insular cortex (detected in 70% of samples), is not limited to the V304I mutation, and oxidative stress plays a larger mechanistic role than the V304I mutation in promoting aggregation in neuroblastoma cells.\",\n      \"method\": \"Insoluble fraction purification from postmortem human cortex; western blotting; oxidative stress induction in neuroblastoma cells; fractionation\",\n      \"journal\": \"Journal of personalized medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct biochemical fractionation of postmortem human brain tissue plus cellular mechanistic experiments; single lab\",\n      \"pmids\": [\"34834422\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"miR-17 post-transcriptionally regulates NPAS3 by binding to the NPAS3 3' UTR, as demonstrated by luciferase reporter assays, contributing to the dissociation between declining NPAS3 mRNA and increasing NPAS3 protein during human postnatal cortical development.\",\n      \"method\": \"Luciferase reporter assays with NPAS3 3' UTR; western blotting; microarray and qRT-PCR in postmortem human brain tissue\",\n      \"journal\": \"Schizophrenia bulletin\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct reporter assay demonstrating functional miR-17 binding to 3' UTR, validated in human postmortem tissue; single lab\",\n      \"pmids\": [\"22228753\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"NPAS3 is a critical regulator of astrogenesis in the developing cortex; Npas3 knockout impairs the differentiation trajectory from radial glia to astrocytes (shown by single-cell transcriptomics). ChIP-seq in primary cortical astrocytes shows NPAS3 binds chromatin targets involved in brain development and synapse organization. Astrocyte-specific Npas3 knockdown causes synaptic and behavioral deficits, and NPAS3-impaired astrogenesis induces synaptic deficits in wild-type neurons in co-culture.\",\n      \"method\": \"Npas3 KO mouse; single-cell RNA-seq; ChIP-seq in primary cortical astrocytes; astrocyte-specific in vivo knockdown; neuron-astrocyte co-culture assay; behavioral testing\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (scRNA-seq, ChIP-seq, in vivo KD, co-culture), cell-type-specific dissection of mechanism\",\n      \"pmids\": [\"36044858\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Npas3 knockdown in cortical neural progenitor cells impairs neuronal radial migration, changes laminar cell fate, and promotes stemness maintenance and increased proliferation of radial glial cells in the VZ/SVZ, indicating that Npas3 regulates the transition from progenitor proliferation to neuronal differentiation and migration in the developing cerebral cortex.\",\n      \"method\": \"In utero knockdown of Npas3 in cortical VZ progenitors; histological and immunofluorescence analysis of cortical lamination and progenitor markers\",\n      \"journal\": \"Frontiers in cellular neuroscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo loss-of-function with defined cellular phenotypes; single lab, single primary method\",\n      \"pmids\": [\"36313621\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"A covalent compound (Compound 6) blocks NPAS3-ARNT heterodimer formation by covalently binding to ARNT Cys336, effectively down-regulating NPAS3 transcriptional function at the cellular level; this identifies ARNT Cys336 as the binding site and the 5-nitrothiazole-2-sulfydryl group as a cysteine-targeting warhead for disrupting the NPAS3-ARNT interface.\",\n      \"method\": \"Biochemical NPAS3-ARNT heterodimer formation assay (EC50 measurement); cellular transcriptional reporter assays; covalent inhibitor medicinal chemistry and structure-activity relationship\",\n      \"journal\": \"Bioorganic chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — biochemical and cellular assays identifying specific covalent binding site on ARNT; single lab, two orthogonal assay levels\",\n      \"pmids\": [\"37352720\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"In astrocytes, AEBP1 sequesters NPAS3 in the cytoplasm, preventing its nuclear binding to the Lipa promoter; when AEBP1 is overexpressed, NPAS3 fails to activate LIPA transcription, leading to lipid droplet accumulation, excess cholesteryl ester storage, lysosomal Aβ retention, and worsened Alzheimer's pathology in 5×FAD mice.\",\n      \"method\": \"Astrocyte-specific AEBP1 knockdown/overexpression in 5×FAD mice; hippocampal transcriptomics and metabolomics; LIPA promoter binding assay; NPAS3 cytoplasmic sequestration demonstrated by protein localization; in vitro cultured astrocyte experiments\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo and in vitro mechanistic dissection with promoter binding evidence; single lab, multiple orthogonal approaches\",\n      \"pmids\": [\"41880326\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"NPAS3 functions as a direct target of miR-122 in endothelial cells; NPAS3 silencing abolishes the anti-EndMT (endothelial-to-mesenchymal transition) effect of miR-122 inhibition, placing NPAS3 downstream of miR-122 in the regulation of EndMT and atherosclerosis.\",\n      \"method\": \"miR-122 mimic/inhibitor transfection in endothelial cells; NPAS3 siRNA knockdown; western blotting for endothelial and mesenchymal markers; lenti-virus injection in ApoE-/- mice\",\n      \"journal\": \"Life sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — epistasis established by NPAS3 knockdown rescuing miR-122 inhibitor phenotype; in vitro and in vivo; single lab\",\n      \"pmids\": [\"33278397\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"The lncRNA 3222401L13Rik mediates its effects on astrocyte neuronal-support gene expression through interaction with NPAS3; overexpression of NPAS3 rescues the functional deficits in astrocytes caused by 3222401L13Rik knockdown.\",\n      \"method\": \"lncRNA knockdown in primary astrocytes; NPAS3 overexpression rescue assay; interaction between lncRNA and NPAS3 demonstrated\",\n      \"journal\": \"Non-coding RNA\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single lab, rescue experiment supporting interaction but mechanism of lncRNA-NPAS3 interaction not fully characterized at molecular level from abstract\",\n      \"pmids\": [\"39846680\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"NPAS3 is a bHLH-PAS transcription factor that obligatorily heterodimerizes with ARNT (via bHLH and PAS domains) to bind DNA and activate target genes including VGF, SHH, and LIPA while repressing SPRY2 and glycolysis genes; its crystal structure reveals four putative ligand-binding pockets; it is regulated post-transcriptionally by miR-17 and post-translationally by cytoplasmic sequestration via AEBP1; it controls adult hippocampal neurogenesis (acting in maturing rather than proliferating precursors), cortical astrogenesis, lung branching morphogenesis via FGF/SHH signaling, and endothelial-mesenchymal transition; and disease-associated mutations or oxidative stress promote its aggregation into insoluble forms that reduce functional soluble NPAS3 and alter transcriptional activity.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"NPAS3 is a bHLH-PAS transcription factor that governs neurodevelopmental and metabolic gene programs by obligatorily heterodimerizing with ARNT to bind DNA and regulate target genes [#0, #1]. Crystal structures of multi-domain NPAS3-ARNT-DNA complexes establish that productive DNA binding requires the heterodimer and reveal four putative ligand-binding pockets, defining NPAS3 as a candidate multi-ligand-sensing factor [#0]; dimerization occurs through both the bHLH and PAS domains, while a C-terminal transactivation domain drives gene activation [#1]. Through this complex NPAS3 activates targets including VGF and Shh and represses Spry2 and multiple glycolysis genes, coupling neurodevelopmental transcription to glucose metabolism [#1, #2, #4]. NPAS3 is required for lung branching morphogenesis via FGF/SHH signaling, with exogenous FGF10 rescuing the Npas3-null defect [#4], and it controls cortical development by regulating progenitor-to-neuron transitions, radial migration, and astrogenesis, where ChIP-seq defines targets in brain development and synapse organization [#12, #13]. Its activity is constrained post-transcriptionally by miR-17 binding to the 3' UTR [#11] and post-translationally by AEBP1-mediated cytoplasmic sequestration, which blocks NPAS3 from activating Lipa and promotes lipid and amyloid pathology in astrocytes [#15]. Disease-associated truncation variants abolish transcriptional activity by preventing ARNT2 heterodimerization [#9], and the schizophrenia-segregating V304I mutation, like oxidative stress, drives NPAS3 into insoluble aggregates that deplete functional soluble protein [#8, #10].\",\n  \"teleology\": [\n    {\n      \"year\": 2004,\n      \"claim\": \"Established that NPAS3 operates within inhibitory interneurons to govern a specific molecular program, moving it from an orphan factor to a defined neuronal regulator.\",\n      \"evidence\": \"Immunohistochemistry plus NPAS1/NPAS3 double-knockout mice showing reduced reelin expression and behavioral deficits\",\n      \"pmids\": [\"15347806\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Does not show direct binding of NPAS3 to the reelin gene\", \"Confounded by simultaneous loss of NPAS1\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Defined the in vivo developmental consequence of NPAS3 loss, linking it to brain morphogenesis and postsynaptic signaling.\",\n      \"evidence\": \"Npas3 knockout mouse with neuroanatomical defects, altered PSD-95, and neurotransmitter pharmacology\",\n      \"pmids\": [\"16190882\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Phenotypes are downstream and do not identify direct transcriptional targets\", \"Mechanism connecting NPAS3 to PSD-95 unresolved\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Identified direct transcriptional targets of NPAS3 and a tissue role outside the brain, showing it activates Shh and represses Spry2 to drive FGF/SHH-dependent lung branching.\",\n      \"evidence\": \"Npas3-null mouse with reduced Shh/Fgf9/Fgf10/Bmp4 and increased Spry2, promoter reporter assays, and FGF10 rescue\",\n      \"pmids\": [\"19581591\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not resolve the dimerization partner required for these promoter activities\", \"Direct E-box occupancy in vivo not mapped\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Connected NPAS3 transcription to metabolism and localized it to the maturation phase of adult neurogenesis, revealing a dual neurodevelopmental and metabolic role.\",\n      \"evidence\": \"Microarray of NPAS3-overexpressing HEK293 cells (VGF induction, glycolysis repression), KO mouse brain metabolomics, and subgranular-zone immunofluorescence\",\n      \"pmids\": [\"21709683\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Metabolic gene repression not shown to be via direct promoter binding\", \"Mechanism linking NPAS3 to NAD+/Krebs intermediates unresolved\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Explained the post-transcriptional uncoupling of NPAS3 mRNA and protein during cortical development by identifying miR-17 control of its 3' UTR.\",\n      \"evidence\": \"Luciferase 3' UTR reporter assays plus expression profiling in postmortem human cortex\",\n      \"pmids\": [\"22228753\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Does not establish whether miR-17 regulation alters NPAS3 transcriptional output\", \"Single miRNA examined\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Solved the structural and mechanistic basis of NPAS3 DNA binding, proving obligate ARNT heterodimerization and revealing candidate ligand pockets.\",\n      \"evidence\": \"X-ray crystallography of multi-domain NPAS3-ARNT-DNA complexes\",\n      \"pmids\": [\"27782878\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Endogenous ligands for the four pockets unidentified\", \"Does not address tissue-specific cofactor selection\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Refined the VGF activation mechanism, showing NPAS3 acts in part through NF-\\u03baB signaling rather than solely direct E-box binding, and links VGF to proliferation.\",\n      \"evidence\": \"Reporter assays with mutated E-box/\\u03baB sites, NF-\\u03baB western blotting, and VGF-knockdown proliferation assays in PC12 cells\",\n      \"pmids\": [\"27877109\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct vs. indirect NF-\\u03baB induction not distinguished\", \"Single cell-line system\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Introduced protein aggregation as a disease mechanism, showing a schizophrenia-segregating mutation increases NPAS3 insolubility and alters its activity.\",\n      \"evidence\": \"Wild-type vs. V304I expression in bacterial and mammalian systems, solubility fractionation, and reporter assays\",\n      \"pmids\": [\"27867938\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Causality from a single small family\", \"Structural basis of aggregation not defined\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Mapped the NPAS3-ARNT interaction to both bHLH and PAS domains and localized the transactivation function and direct VGF/TXNIP promoter binding.\",\n      \"evidence\": \"Reciprocal Co-IP, domain truncation, reporter and promoter binding assays in human cells\",\n      \"pmids\": [\"30509165\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Does not establish in vivo occupancy at these promoters\", \"Regulation of TXNIP physiologic context unexplored\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Established loss-of-function disease variants act by abolishing heterodimerization, tying clinical truncations directly to the dimerization requirement.\",\n      \"evidence\": \"Reporter transcriptional assays and Co-IP with ARNT2 for clinical truncation variants\",\n      \"pmids\": [\"33758288\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Patient phenotype-to-molecular-defect correlation limited\", \"ARNT vs. ARNT2 partner preference in vivo unresolved\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Generalized NPAS3 aggregation beyond a single mutation, implicating oxidative stress as the dominant driver in human cortex.\",\n      \"evidence\": \"Insoluble-fraction purification from postmortem human insular cortex and oxidative-stress induction in neuroblastoma cells\",\n      \"pmids\": [\"34834422\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional consequence of widespread aggregation on neuronal physiology unmeasured\", \"Trigger of oxidative-stress-driven aggregation in vivo unknown\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Defined a cell-autonomous role in astrogenesis with genome-wide target mapping, showing NPAS3 in astrocytes is needed for synapse organization and behavior.\",\n      \"evidence\": \"Npas3 KO single-cell RNA-seq, astrocyte ChIP-seq, astrocyte-specific in vivo knockdown, and neuron-astrocyte co-culture\",\n      \"pmids\": [\"36044858\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Individual functional targets among ChIP-seq peaks not validated\", \"Dependence on ARNT partner in astrocytes not tested\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Showed NPAS3 controls the progenitor-to-neuron transition, regulating proliferation, fate, and radial migration in developing cortex.\",\n      \"evidence\": \"In utero knockdown in cortical VZ progenitors with lamination and progenitor-marker analysis\",\n      \"pmids\": [\"36313621\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct transcriptional targets in progenitors not identified\", \"Single primary method\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Placed NPAS3 downstream of miR-122 in vascular biology, extending its role to endothelial-to-mesenchymal transition and atherosclerosis.\",\n      \"evidence\": \"miR-122 mimic/inhibitor with NPAS3 siRNA epistasis in endothelial cells and ApoE-/- mouse experiments\",\n      \"pmids\": [\"33278397\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct miR-122 binding to NPAS3 transcript versus indirect effect not fully resolved\", \"Transcriptional targets mediating EndMT unidentified\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Provided pharmacological proof that disrupting the NPAS3-ARNT interface is feasible, identifying ARNT Cys336 as a covalent targeting site.\",\n      \"evidence\": \"Biochemical heterodimer-formation assay and cellular reporter assays with a covalent 5-nitrothiazole-2-sulfydryl compound\",\n      \"pmids\": [\"37352720\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Selectivity over other ARNT-dependent dimers untested\", \"In vivo efficacy not demonstrated\"]\n    },\n    {\n      \"year\": 2026,\n      \"claim\": \"Revealed post-translational control of NPAS3 by cytoplasmic sequestration, linking AEBP1-blocked LIPA activation to astrocyte lipid handling and Alzheimer's pathology.\",\n      \"evidence\": \"Astrocyte-specific AEBP1 knockdown/overexpression in 5xFAD mice, transcriptomics/metabolomics, LIPA promoter binding, and localization assays\",\n      \"pmids\": [\"41880326\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct physical AEBP1-NPAS3 interaction interface not mapped\", \"Single disease model\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The endogenous ligands occupying the four NPAS3-ARNT pockets and how ligand or partner choice (ARNT vs ARNT2) selects target programs across neurons, astrocytes, lung, and endothelium remain unknown.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No identified physiological ligand for the structural pockets\", \"Determinants of cell-type-specific target selection unresolved\", \"Relationship between aggregation, sequestration, and transcriptional output not unified mechanistically\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [0, 1, 2, 4, 12]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [0, 1, 12]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [0, 1, 15]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [15]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [0, 1, 4, 12]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [4, 12, 13]}\n    ],\n    \"complexes\": [\"NPAS3-ARNT heterodimer\"],\n    \"partners\": [\"ARNT\", \"ARNT2\", \"AEBP1\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":6,"faith_total":6,"faith_pct":100.0}}